[{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ JanOne"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"Cato Research","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Cato Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cato Research \/ JanOne","highestDevelopmentStatusID":"5","companyTruncated":"Cato Research \/ JanOne"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sustained-Release Oral Formulation","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nitric Oxide Innovations \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxide Innovations \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"A.G.P.\/Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"JanOne \/ A.G.P.\/Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ A.G.P.\/Alliance Global Partners"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sustained Release Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"SPYR Technologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Sustained-Release","sponsorNew":"JanOne \/ SPYR Technologies","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ SPYR Technologies"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for CAS-7632-00-0

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.

Brand Name : JAN 101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 13, 2023

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.

Brand Name : JAN 101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 22, 2023

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Recent studies have in fact suggested that PAD is a microvascular disease, so the observation that JAN101 (Sodium nitrite) improves microvascular and nerve function is crucial in treating this disease.

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 07, 2022

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Sale of GeoTraq, a wholly-owned subsidiary of JanOne to SPYR Technologies will help main business continue to fund the necessary clinical trials for JAN101 (TV1001SR), a slow-release formulation of sodium nitrite used for treatment for peripheral artery ...

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : $13.5 million

May 31, 2022

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : SPYR Technologies

Deal Size : $13.5 million

Deal Type : Divestment

blank

05

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of Peripheral Artery Disease (PAD).

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 28, 2021

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The primary endpoint will be the ability of patients to walk without pain or muscle fatigue as a result of vascular function restored by JAN101.

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 22, 2021

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : JAN101 is intended to address the 8.5 million Americans who may have PAD. One of the more encouraging outcomes from patients who participated in early Phase 1 and Phase 2a trials of JAN101 was a reported reduction in associated PAD pain.

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 23, 2021

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JAN101 is highly selective, acting only in damaged tissue.

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 08, 2021

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including planning of clinical trials for JAN101, the company’s lead drug candidate.

Brand Name : JAN101

Molecule Type : Small molecule

Upfront Cash : Undisclosed

February 02, 2021

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : A.G.P./Alliance Global Partners

Deal Size : $6.0 million

Deal Type : Public Offering

blank

10

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : NOviricid is the first oral NO generating drug to be clinically tested to treat African Americans with COVID-19. NOviricid offers a fast acting, Nitric Oxide therapeutic, with proven vasodilatory and anti-viral properties, targeting the effects of the no...

Brand Name : NOviricid

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 26, 2020

Lead Product(s) : Sodium Nitrite

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II/ Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank